Vanguard Group Inc Tempest Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 176,193 shares of TPST stock, worth $160,335. This represents 0.0% of its overall portfolio holdings.

Number of Shares

176,193

Previous 176,193 -0.0%

Holding current value

$160,335

Previous $385,000 36.1%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.23 - $9.77 $8,307 - $352,892	-36,120 Reduced 17.01%	176,193 $775,000
Q3 2023 Nov 14, 2023	SELL	$0.3 - $1.39 $29,258 - $135,562	-97,527 Reduced 31.48%	212,313 $63,000
Q2 2023 Aug 14, 2023	BUY	$1.12 - $3.76 $67,075 - $225,182	59,889 Added 23.96%	309,840 $393,000
Q1 2023 May 15, 2023	BUY	$1.14 - $2.91 $10,246 - $26,155	8,988 Added 3.73%	249,951 $579,000
Q4 2022 Feb 10, 2023	BUY	$1.15 - $2.12 $231 - $426	201 Added 0.08%	240,963 $277,000
Q3 2022 Nov 14, 2022	SELL	$1.62 - $2.76 $12,169 - $20,733	-7,512 Reduced 3.03%	240,762 $419,000
Q2 2022 Aug 12, 2022	SELL	$2.08 - $4.15 $1,693 - $3,378	-814 Reduced 0.33%	248,274 $534,000
Q1 2022 May 13, 2022	SELL	$2.27 - $5.45 $95,839 - $230,099	-42,220 Reduced 14.49%	249,088 $842,000
Q4 2021 Feb 14, 2022	SELL	$5.28 - $15.2 $358,290 - $1.03 Million	-67,858 Reduced 18.89%	291,308 $1.54 Million
Q3 2021 Nov 12, 2021	BUY	$10.49 - $24.19 $3.13 Million - $7.21 Million	298,016 Added 487.35%	359,166 $5.2 Million
Q2 2021 Aug 13, 2021	BUY	$11.18 - $22.95 $683,657 - $1.4 Million	61,150 New	61,150 $683,000

Others Institutions Holding TPST

# of Institutions

Shares Held

2.4M

Call Options Held

44.9K

Put Options Held

109K

View Full List

About Tempest Therapeutics, Inc.

Ticker TPST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,418,900
Market Cap $9.48M
Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...

More about TPST

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Tempest Therapeutics, Inc. Transaction History